search

Active clinical trials for "Lymphoma, T-Cell, Cutaneous"

Results 241-250 of 294

Mindfulness Interventions and Cutaneous T Cell Lymphoma (CTCL)

AnxietyQuality of Life

The primary objective is to assess the feasibly, adherence, and effects of mindfulness-based stress reduction (MBSR) on anxiety and health-related quality of life in adult patients with cutaneous T-cell lymphoma at the Yale Cancer Center/Smilow Cancer Hospital. Participants will attend group sessions led by an instructor experienced in MBSR in an academic setting. The mindfulness meditation group sessions will take place at the Smilow Cancer Center at the Yale New-Haven Hospital.

Terminated9 enrollment criteria

Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron...

Iron OverloadAccelerated Phase Chronic Myelogenous Leukemia102 more

RATIONALE: Low dose deferasirox may be safe and effective in treating patients who have undergone hematopoietic stem cell transplant and have iron overload. PURPOSE: This pilot clinical trial studies safety and tolerability of deferasirox in hematopoietic stem cell transplant recipients who have iron overload. Effect of low dose deferasirox on labile plasma iron is also examined.

Terminated23 enrollment criteria

Pembrolizumab and Total Skin Electron Beam Radiotherapy in Mycosis Fungoides and Sézary Syndrome...

Cutaneous T-Cell Lymphomas

Hypothesis: Addition of low dose TSEBT to debulk MF/SS either before or during checkpoint blockade with anti-PD-1 pembrolizumab monoclonal antibody therapy will be safe and well tolerated. Primary Objective: • To determine the maximum tolerated dose (MTD) for the combination of total skin electron beam therapy (TSEBT) and pembrolizumab regimen. Secondary Objectives: To determine the preliminary efficacy of the combination of TSEBT with pembrolizumab. To determine the impact on patient-reported health-related quality of life outcomes.

Withdrawn42 enrollment criteria

Trial of Curcumin in Cutaneous T-cell Lymphoma Patients

Cutaneous T-cell Lymphoma

The goal of this clinical research study is to learn if treatment with curcumin can help to decrease the size of lesions and/or decrease itching in patients with MF or SS. The safety of curcumin will also be studied.

Withdrawn23 enrollment criteria

Reduced Intensity Conditioning Before Partially Matched Donor Stem Cell Transplant in Treating Patients...

Cutaneous T-Cell Non-Hodgkin LymphomaRecurrent Mycosis Fungoides and Sezary Syndrome5 more

This phase I trial studies the side effects and the best dose of donor lymphocyte infusion when given together with reduced intensity conditioning regimen before partially matched donor stem cell transplant in treating patients with stage IIB-IV mycosis fungoides or Sezary syndrome. Giving chemotherapy and low-dose total-body irradiation followed by high-dose cyclophosphamide before a donor peripheral blood stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells (called graft-versus-host disease). Removing the T-cells from the donor cells and giving them before transplant may stop this from happening. Additionally, giving tacrolimus and mycophenolate mofetil before and after transplant may also stop this from happening.

Withdrawn24 enrollment criteria

Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas...

CD30-Positive Neoplastic Cells PresentFolliculotropic Mycosis Fungoides5 more

This phase I trial studies the side effects and best dose of lenalidomide when given together with brentuximab vedotin in treating patients with T-cell lymphomas that have come back or do not respond to treatment. Monoclonal antibodies, such as brentuximab vedotin, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving brentuximab vedotin and lenalidomide may work better in treating patients with T-cell lymphomas.

Withdrawn58 enrollment criteria

Study Of Intratumoral G100 In Cutaneous T Cell Lymphoma

LymphomaT-Cell1 more

The overall goal of this study is to evaluate the safety and immunogenicity of repeat-dose intratumoral G100 administration in patients with Cutaneous T Cell Lymphoma (CTCL) alone (Part 1) and following standard local radiation therapy or topical nitrogen mustard application (Part 2). Plaque, patch, or tumor lesions of CTCL may be injected. Disease will be assessed in all sites, including skin, nodes, and blood.

Withdrawn25 enrollment criteria

Analysis of Genes Present in Cutaneous T-cell Lymphoma Cells

Lymphoma

RATIONALE: Analyzing genes that are present in cancer cells may be useful in developing better methods to detect, predict, and treat cutaneous T-cell lymphoma. PURPOSE: Clinical trial to study genes that are present in cutaneous T-cell lymphoma cells.

Completed39 enrollment criteria

Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic...

Accelerated Phase Chronic Myelogenous LeukemiaAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome53 more

This study will determine the safety and applicability of experimental forms of umbilical cord blood (UCB) transplantation for patients with high risk hematologic malignancies who might benefit from a hematopoietic stem cell transplant (HSCT) but who do not have a standard donor option (no available HLA-matched related donor (MRD), HLA-matched unrelated donor (MUD)), or single UCB unit with adequate cell number and HLA-match).

Withdrawn38 enrollment criteria

Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell Lymphoma

Mycosis Fungoides

This study is being conducted by Brian Poligone, MD PhD. The purpose of this study is to determine safety, effectiveness, and tolerability of two topical therapies, imiquimod and fluocinonide, for patients with early stage Cutaneous T-cell Lymphoma (CTCL).

Withdrawn17 enrollment criteria
1...242526...30

Need Help? Contact our team!


We'll reach out to this number within 24 hrs